1. HER2 loss in HER2‐positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. Issue 12 (16th September 2016) Authors: Pietrantonio, F.; Caporale, M.; Morano, F.; Scartozzi, M.; Gloghini, A.; De Vita, F.; Giommoni, E.; Fornaro, L.; Aprile, G.; Melisi, D.; Berenato, R.; Mennitto, A.; Volpi, C. C.; Laterza, M. M.; Pusceddu, V.; Antonuzzo, L.; Vasile, E.; Ongaro, E.; Simionato, F.; de Braud, F. Journal: International journal of cancer Issue: Volume 139:Issue 12(2016:Dec. 15) Page Start: 2859 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Nab paclitaxel (Nab-P) and gemcitabine (G) first line chemotherapy (CT) in metastatic pancreatic cancer (mPC) patients (pts) relapsed after adjuvant treatment (ADJ T): A "real life" study. (February 2017) Authors: Giordano, G.; Lo Re, G.; Milella, M.; Di Marco, M.; Melisi, D.; Passardi, A.; Iop, A.; Febbraro, A.; Foltran, L.; Francesca, B.; Bertocchi, P.; Vaccaro, V.; Aloi, M.B.; Giommoni, E.; Ricci, V.; Vasile, E.; Zaniboni, A.; Zagone, V.; De Vita, F. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S87 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗